AstraZeneca’s Forxiga (dapagliflozin) Receives MHLW’s Approval for Type-1 Diabetes (T1D) in Japan

 AstraZeneca’s Forxiga (dapagliflozin) Receives MHLW’s Approval for Type-1 Diabetes (T1D) in Japan

AstraZeneca’s Forxiga (dapagliflozin) Receives MHLW’s Approval for Type-1 Diabetes (T1D) in Japan

Shots:

  • The approval is based on P-III DEPICT & D1695C00001 study results assessing Forxiga (5/10 mg) vs PBO in patients with T1D inadequately controlled by insulin for 28 to 52 wks.
  • The study resulted in meeting its 1EPs & 2EPs as reductions in average blood glucose levels HbA1c, weight and total daily insulin dose for 24 wks.
  • Forxiga (dapagliflozinm, qd, PO) is a novel inhibitor of human sodium-glucose co-transporter 2 (SGLT2) approved by European Commission on Mar 20, 2019 and is currently under review by the US FDA as an adjunct treatment to insulin in adults with expected results in H2’19

Click here to read full press release/ article | Ref: Astrazeneca | Image: AstraZeneca US

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post